BACKGROUND: Reductions in AIDS-related morbidity and mortality following the advent of combination antiretroviral therapy have coincided with relative increases in chronic non-AIDS end-organ diseases among HIV+ patients. OBJECTIVE: To examine the association of latest CD4+ counts with risk of non-AIDS diseases in a cohort of 1397 patients who initiate antiretroviral therapy. METHODS: CD4+ counts and HIV RNA levels along with fatal, and non-fatal, AIDS and non-AIDS diseases (liver, cardiovascular, renal, and cancer) were assessed over a median follow-up of 5 years. Cox proportional regression models were used to study risk associations. RESULTS: A total of 227 patients experienced an AIDS event and 80 patients developed a non-AIDS disease event. Both AIDS and non-AIDS diseases rates (events/100 person-years), respectively, declined with higher latest CD4+ counts: 13.8 and 2.1 with latest CD4+ counts less than 200 cells/microl; 2.0 and 1.7 for counts of 200-350 cells/microl; and 0.7 and 0.7 for counts greater than 350 cells/microl. After adjusting for baseline covariates and the latest HIV RNA level, risk of AIDS and non-AIDS diseases were lowered by 44% (95% confidence interval for hazard ratio 0.50-0.62, P < 0.01) and 14% (95% confidence interval for hazard ratio 0.77-0.96, P = 0.01), respectively, for each 100 cell/microl higher latest CD4+ count. CONCLUSION: Higher CD4+ counts on antiretroviral therapy are associated with lower rates of non-AIDS diseases and AIDS. These findings expand our understanding of the implications of HIV-related immunodeficiency and motivate randomized studies to evaluate the effects of antiretroviral therapy on a broad set of clinical outcomes at CD4+ counts greater than 350 cells/microl.
BACKGROUND: Reductions in AIDS-related morbidity and mortality following the advent of combination antiretroviral therapy have coincided with relative increases in chronic non-AIDS end-organ diseases among HIV+ patients. OBJECTIVE: To examine the association of latest CD4+ counts with risk of non-AIDS diseases in a cohort of 1397 patients who initiate antiretroviral therapy. METHODS:CD4+ counts and HIV RNA levels along with fatal, and non-fatal, AIDS and non-AIDS diseases (liver, cardiovascular, renal, and cancer) were assessed over a median follow-up of 5 years. Cox proportional regression models were used to study risk associations. RESULTS: A total of 227 patients experienced an AIDS event and 80 patients developed a non-AIDS disease event. Both AIDS and non-AIDS diseases rates (events/100 person-years), respectively, declined with higher latest CD4+ counts: 13.8 and 2.1 with latest CD4+ counts less than 200 cells/microl; 2.0 and 1.7 for counts of 200-350 cells/microl; and 0.7 and 0.7 for counts greater than 350 cells/microl. After adjusting for baseline covariates and the latest HIV RNA level, risk of AIDS and non-AIDS diseases were lowered by 44% (95% confidence interval for hazard ratio 0.50-0.62, P < 0.01) and 14% (95% confidence interval for hazard ratio 0.77-0.96, P = 0.01), respectively, for each 100 cell/microl higher latest CD4+ count. CONCLUSION: Higher CD4+ counts on antiretroviral therapy are associated with lower rates of non-AIDS diseases and AIDS. These findings expand our understanding of the implications of HIV-related immunodeficiency and motivate randomized studies to evaluate the effects of antiretroviral therapy on a broad set of clinical outcomes at CD4+ counts greater than 350 cells/microl.
Authors: R D MacArthur; L Chen; D L Mayers; C L Besch; R Novak; M van den Berg-Wolf; T Yurik; G Peng; B Schmetter; B Brizz; D Abrams Journal: Control Clin Trials Date: 2001-04
Authors: V Panichi; M Migliori; S De Pietro; D Taccola; A M Bianchi; M Norpoth; M R Metelli; L Giovannini; C Tetta; R Palla Journal: Ren Fail Date: 2001 May-Jul Impact factor: 2.606
Authors: A Mocroft; R Brettle; O Kirk; A Blaxhult; J M Parkin; F Antunes; P Francioli; A D'Arminio Monforte; Z Fox; J D Lundgren Journal: AIDS Date: 2002-08-16 Impact factor: 4.177
Authors: Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2003-11-20 Impact factor: 91.245
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: D M Coviello; R Lovato; K Apostol; M M Eisenberg; D S Metzger; R Szucs-Reed; N Kiryankova-Dalseth; D Kelly; A Jackson; M Plano; M B Blank Journal: Community Ment Health J Date: 2018-05-11
Authors: Eleanor M P Wilson; Amrit Singh; Katherine Huppler Hullsiek; Dave Gibson; W Keith Henry; Ken Lichtenstein; Nur F Önen; Erna Kojic; Pragna Patel; John T Brooks; Irini Sereti; Jason V Baker Journal: J Infect Dis Date: 2014-05-09 Impact factor: 5.226
Authors: Caroline O Tabler; Mark B Lucera; Aiman A Haqqani; David J McDonald; Stephen A Migueles; Mark Connors; John C Tilton Journal: J Virol Date: 2014-02-19 Impact factor: 5.103